An open‐label study on ulotaront's effects on insulin‐glucose regulation in schizophrenia patients with metabolic syndrome and prediabetes: Part I
Despite limited sample size, primary endpoints favoured ulotaront over prior antipsychotics with respect to a reduction trend in glucose, c-peptide and insulin. The insulin response after a solid meal was nominally significant, suggesting that semi-chronic twice-a-day dosing of ulotaront might improve insulin dynamics in schizophrenia patients at high diabetes risk.
Authors
- Snezana Milanovic (ORCID: https://orcid.org/0009-0000-7586-1583)
- Clay Dehn
- Yu‐Luan Chen (ORCID: https://orcid.org/0000-0002-2866-3602)
- Robert Lew
- Kuangnan Xiong (ORCID: https://orcid.org/0009-0006-4898-539X)
- Yongquan Lai
- Seth C. Hopkins (ORCID: https://orcid.org/0000-0003-3999-2281)
- Gerald R. Galluppi (ORCID: https://orcid.org/0000-0001-6705-3084)
- Kenneth S. Koblan (ORCID: https://orcid.org/0000-0001-6103-2629)
- Manu V. Chakravarthy (ORCID: https://orcid.org/0000-0002-3699-150X)
- Emily Casavant
Institutions
- Edison Pharmaceuticals (United States) (US)
- Sumitomo Dainippon Pharma (United States) (US)
- Carmot Therapeutics (United States) (US)
- University of Jamestown (US)
Publication Details
- Journal
- Diabetes Obesity and Metabolism
- Published
- 2025-10-22
- DOI
- https://doi.org/10.1111/dom.70136
- Citations
- 1
- Primary Topic
- Diabetes Treatment and Management
- Type
- article
- Field-Weighted Citation Impact
- 1.29